{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T13:51:44Z","timestamp":1782913904506,"version":"3.54.5"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare, life-threatening cutaneous adverse reactions associated with immune checkpoint inhibitors (ICIs). Evidence guiding optimal management remains limited. We report the case of a 75-year-old woman with stage IV endometrial carcinoma who developed extensive epidermal necrosis three weeks after the second cycle of maintenance pembrolizumab. Skin biopsy confirmed full-thickness epidermal necrosis, and the SCORTEN score was 3, predicting a high risk of mortality. There was no significant ocular or mucosal involvement. The patient was treated with etanercept, cyclosporine, and pulse methylprednisolone, followed by tapering oral corticosteroids alongside meticulous supportive care. Epidermal detachment stabilized rapidly after therapy and early re-epithelialization occurred within 10 days. The case highlights the importance of early recognition and judicious use of combination immunomodulatory therapy leading to improved outcomes. Multidisciplinary management is essential.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1872034","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T13:40:18Z","timestamp":1782913218000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Successful management of pembrolizumab-associated Stevens-Johnson syndrome\/toxic epidermal necrolysis in a patient with uterine serous carcinoma: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Tasabeeh","family":"Hamad","sequence":"first","affiliation":[{"name":"Pharmacy Department, Sultan Qaboos Comprehensive Cancer Care and Research Center, University Medical City","place":["Muscat, Oman"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Maria","family":"Serrano","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Family Medicine and Community Health (FAMCO) Department, Sultan Qaboos University Hospital, University Medical City","place":["Muscat, Oman"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaher","family":"Al Kaabi","sequence":"additional","affiliation":[{"name":"Dermatology Resident, Oman Medical Specialty","place":["Muscat, Oman"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiya","family":"Al Bahri","sequence":"additional","affiliation":[{"name":"Department of Pathology, Sultan Qaboos University Hospital and College of Medicine and Health Sciences, University Medical City","place":["Muscat, Oman"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kefah","family":"Hassan","sequence":"additional","affiliation":[{"name":"Nursing Department, Sultan Qaboos Comprehensive Cancer Care and Research Center, University Medical City","place":["Muscat, Oman"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bushra","family":"Salman","sequence":"additional","affiliation":[{"name":"Pharmacy Department, National Hematology and Bone Marrow Transplantation Center, University Medical City","place":["Muscat, Oman"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikram A.","family":"Burney","sequence":"additional","affiliation":[{"name":"Women Health Program, Sultan Qaboos Comprehensive Cancer Care and Research Center, University Medical City","place":["Muscat, Oman"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe adverse cutaneous reactions to drugs","volume":"331","author":"Roujeau","year":"1994","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.03.023","article-title":"Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults","volume":"136","author":"Hsu","year":"2016","journal-title":"J Invest Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.510","article-title":"Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"133","author":"Sekula","year":"2013","journal-title":"J Invest Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1071","article-title":"The medication risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in Asians: the major drug causality and comparison with the US FDA label","volume":"105","author":"Wang","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.03.026","article-title":"Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients","volume":"81","author":"Saw","year":"2017","journal-title":"Eur J Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14811","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review","volume":"59","author":"Maloney","year":"2020","journal-title":"Int J Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.10.058","article-title":"Idiopathic Stevens-Johnson syndrome and toxic epidermal necrolysis: prevalence and patients' characteristics","volume":"80","author":"Chaby","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.04.066","article-title":"Mycoplasma-induced Stevens-Johnson syndrome\/toxic epidermal necrolysis: case-control analysis of a cohort managed in a specialized center","volume":"86","author":"Liew","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2004.23439.x","article-title":"Evaluation of the potential role of cytokines in toxic epidermal necrolysis","volume":"123","author":"Nassif","year":"2004","journal-title":"J Invest Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100951","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis in patients treated with immune checkpoint inhibitors: a safety analysis of clinical trials and FDA pharmacovigilance database","volume":"37","author":"Zhu","year":"2021","journal-title":"EClinicalMedicine"},{"key":"B13","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3109\/08820538.2015.1115255","article-title":"Immunologic mediators in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"31","author":"Saeed","year":"2016","journal-title":"Semin Ophthalmol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1414136","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis associated with immune checkpoint inhibitors: a systematic review","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14591","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: an analysis of the US Food and Drug Administration Adverse Event Reporting System","volume":"59","author":"Borrelli","year":"2018","journal-title":"Epilepsia"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13925","article-title":"The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptic drugs","volume":"58","author":"Frey","year":"2017","journal-title":"Epilepsia"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2016.02.006","article-title":"Maculopapular type drug eruption caused by pregabalin: a case and literature review","volume":"65","author":"Inoue","year":"2016","journal-title":"Allergol Int"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200528100-00008","article-title":"Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors","volume":"28","author":"La Grenade","year":"2005","journal-title":"Drug Saf"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-1873.2004.00271i.x","article-title":"Cutaneous reaction to oral celecoxib with positive patch test","volume":"50","author":"Alonso","year":"2004","journal-title":"Contact Dermatitis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1592\/phco.22.13.1193.33513","article-title":"Toxic epidermal necrolysis after celecoxib therapy","volume":"22","author":"Berger","year":"2002","journal-title":"Pharmacotherapy"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"B22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","article-title":"Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor","volume":"60","author":"Belum","year":"2016","journal-title":"Eur J Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219890659","article-title":"Toxic epidermal necrolysis associated with pembrolizumab","volume":"26","author":"Cai","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.24748.1","article-title":"Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Hasegawa","year":"2020","journal-title":"F1000Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2025-0294-RA","article-title":"Immune checkpoint inhibitor\u2013related epidermal necrosis: terminology, pathology, and clinical implications","author":"Brent","year":"2025","journal-title":"Arch Pathol Lab Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.jaip.2022.01.038","article-title":"Evaluation of combination therapy with etanercept and systemic corticosteroids for Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: a multicenter observational study","volume":"10","author":"Zhang","year":"2022","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1872034\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T13:40:19Z","timestamp":1782913219000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1872034\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":26,"alternative-id":["10.3389\/fimmu.2026.1872034"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1872034","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"article-number":"1872034"}}